Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
Rhea-AI Summary
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has commenced a proposed underwritten public offering of common stock and, for certain investors, pre-funded warrants as an alternative to common shares. All securities will be issued and sold by the company, which expects to grant underwriters a 30-day option to purchase up to an additional 15% of common shares on the same terms.
According to Zentalis, net proceeds, combined with existing cash and marketable securities, are intended to fund clinical and preclinical development of its WEE1 inhibitor azenosertib and other programs, regulatory filings, manufacturing, companion diagnostic work, pre-commercial activities, capital expenditures, working capital and general corporate purposes. TD Cowen, Guggenheim Securities and Oppenheimer & Co. are joint bookrunners. The offering will be made under an effective SEC shelf registration statement.
Positive
- Primary equity raise via underwritten public offering with all securities sold by the company
- 15% underwriters’ option to purchase additional common shares, potentially increasing total capital raised
- Broad use of proceeds earmarked for clinical trials, regulatory filings, manufacturing and pre-commercial activities for azenosertib and other programs
Negative
- Proposed sale of new common shares and pre-funded warrants could dilute existing ZNTL shareholders if the offering is completed
- Offering terms, size and timing remain uncertain, as completion is subject to market and other conditions
News Explained
No offering size or terms are committed yet, so proceeds and potential ownership dilution remain undetermined.
The proposed equity financing remains at the commencement stage: Zentalis says market conditions could prevent or delay completion and leaves the offering’s size and terms unsettled.
If common stock is issued, or pre-funded warrants convert, the total share count can rise and existing holders’ percentage ownership can fall.
The pre-funded warrants are a near-fully paid instrument with a nominal exercise price that converts to common shares on exercise; an underwritten offering uses an investment bank to buy issuer securities and resell them, with fees reducing net proceeds below gross.
As of
The preliminary prospectus supplement that the company says it will file with the SEC is the next stated milestone; that supplement sets final size, price and fees for a specific takedown.
Sources and calculations
- Zentalis proposed underwritten public offering announcement (2026-08-13)
- Dilution definition (undated)
- Pre-funded warrant definition (undated)
- Underwritten offering definition (undated)
- Prospectus supplement purpose (undated)
- Zentalis second-quarter 2026 fundamentals (2026-06-30)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $24,783,000 / ($37,236,000 / 90) = [object Object]
Market reaction after public offering: ZNTL -12.29%
Following this news, ZNTL has declined 12.29%, reflecting a significant negative market reaction. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.64.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | 2Q26 earnings report | Negative | -15.6% | Reported net loss, higher expenses, and clinical updates following a Type D FDA meeting |
| Aug 03 | Inducement grants | Neutral | +5.0% | Granted stock options to two newly hired employees under Nasdaq listing rules |
| Jul 17 | Clinical presentation notice | Neutral | -2.0% | Announced planned ESMO presentations covering DENALI survival data and ASPENOVA |
| Jun 01 | Inducement grants | Neutral | -0.8% | Granted stock options to two newly hired employees under the inducement plan |
| May 27 | Leadership appointments | Neutral | +0.8% | Appointed a director and commercial strategy executive during registrational program advancement |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
ZNTL's recent news reactions were mixed, with the latest earnings report followed by a negative reaction while several informational announcements produced divergent moves.
Key Terms
underwritten public offering financial
pre-funded warrants financial
wee1 inhibitor medical
companion diagnostic medical
shelf registration statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced the commencement of a proposed underwritten public offering of shares of its common stock and in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities to be sold in the proposed offering will be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (
The Company intends to use the net proceeds from the offering, together with the Company’s existing cash, cash equivalents and marketable securities, to fund clinical trials, preclinical studies, regulatory filings, manufacturing and the Company’s companion diagnostic in support of its programs, as well as for pre-commercial activities, capital expenditures, working capital and other general corporate purposes.
TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunners for the offering.
The securities described above are being offered pursuant to an effective shelf registration statement that was filed with the U.S. Securities and Exchange Commission (SEC) on March 26, 2025, and became effective on April 4, 2025. This offering will be made only by means of a prospectus supplement and the accompanying prospectus which forms a part of the effective shelf registration statement.
A preliminary prospectus supplement related to the offering (including the accompanying prospectus) will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement related to the offering and the accompanying prospectus may be obtained, when available, by visiting the SEC’s website or by contacting: TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in this offering in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Certain statements contained in this press release, including, without limitation, those relating to the timing, size and completion of the offering, the planned use of proceeds of the offering, the sufficiency of the proceeds of the offering and the Company’s cash, cash equivalents and marketable securities to fund its operating expenses and capital expenditures, are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the proposed offering, the completion of the offering on the anticipated terms or at all, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the proposed offering, the anticipated use of proceeds of the offering, general economic conditions and other risks identified from time to time in the reports the Company files with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and the final prospectus supplement and accompanying prospectus related to the proposed offering to be filed with the SEC, which are available at www.sec.gov. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of the statements. The Company’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com
